Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors

Symeres rehires Jurgen Berendsen as CFO amid strategic growth push

Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade

Codexis teams up with Axolabs to advance enzymatic RNA manufacturing

The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design

US healthcare costs spark push for Ayurveda integration

Firstsource acquires TeleMedik

The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico

NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma

The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases